Abstract

Volume.120 Number.6

Original article : Case report

A Case of a Corneal Disorder after Breast Cancer Treatment with Nab-paclitaxel
Yuka Hosotani1, Takanobu Morimatsu2, Masashi Takata1, Osamu Mimura1
1 Department of Ophthalmology, Hyogo College of Medicine
2 Department of Ophthalmology, Ino Hospital

Background: We report a case of a corneal disorder after breast cancer treatment with a microtubule inhibitor, nab-paclitaxel (Abraxane).
Case: A 55-year-old woman, who was referred to our clinic, presented with blurred vision. 2 weeks previously, she had been undergoing treatment with nab-paclitaxel, trastuzumab and pertuzumab. Visual acuity was 20/60 in right eye and 20/40 in left eye. Slit-lamp examination showed an atypical epithelium invasion of the cornea in both eyes and small epithelial defect in left eye. After the nab-paclitaxel treatment was discontinued the corneal findings improved. 4 months later, visual acuity was 20/15 in right eye and 20/20 in left eye.
Conclusions: Nab-paclitaxel can cause severe corneal disorders, but the possibility that trastuzumab and pertuzumab combination therapy is associated with these disorders cannot be denied. Clinicians should consider the possibility of the side effects caused by systemic administration in cases of corneal disorders of uncertain etiology.
Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 120:449-453, 2016.

Key words
Nab-paclitaxel (Abraxane), Corneal epithelial disorder, Anti-cancer agent
Reprint requests to
Yuka Hosotani, M.D. Department of Ophthalmology, Hyogo College of Medicine. 1-1 Mukogawa-cho, Nishinomiya-shi, Hyogo-ken 663-8131, Japan